Advertisement


Jean-Charles Soria, MD, PhD, on Results of the Lux Lung 8 Clinical Trial

2015 European Cancer Congress

Advertisement

Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.



Related Videos

Lung Cancer

Tony Mok, MD, and Alice Shaw, MD, PhD: Expert Perspectives on ALK Inhibition and Brigatinib

Tony Mok, MD, of The Chinese University of Hong Kong, and Alice Shaw, MD, PhD, of Massachusetts General Hospital, discuss the current status and future outlook of ALK inhibition, and an assessment of brigatinib CNS activity in patients with ALK-positive non-small cell lung cancer and intracranial metastases (Abstract 3061).

Global Cancer Care

Milena Sant, MD, on The Latest Findings From the EUROCARE 5 Study

Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).

Lung Cancer

Benjamin Besse, MD, PhD, and Tony Mok, MD, on Results of the BIRCH Clinical Trial

Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected NSCLC (Abstract 17LBA).

Bladder Cancer

Jonathan E. Rosenberg, MD, on Results of the IMvigor 210 Study on Atezolizumab in Locally Advanced or Metastatic Urothelial Cancer

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses this pivotal study of an investigational immunotherapy that has shown increased and durable responses, with a relatively benign toxicity profile (Abstract 21LBA).

Lung Cancer

Jean-Charles Soria, MD, PhD, on Results of the KEYNOTE 001 Clinical Trial

Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: the efficacy and safety of pembrolizumab in previously treated non-small cell lung cancer (Abstract LBA33).

Advertisement

Advertisement




Advertisement